Oxygen Therapeutics: Perfluorocarbons and Blood Substitute Safety
Oxygen Therapeutics: Perfluorocarbons and Blood Substitute Safety
复制标题
DOI：
10.1016/j.ccc.2008.12.007
复制
发表时间：
2009-04-01
影响因子：
4.3
通讯作者：
Cushing, Melissa M.
中科院分区：
文献类型：
--
作者：
Cohn, Claudia S.;Cushing, Melissa M.
发达国家和发展中国家目前对血液供应的需求将随着时间的推移而增加。红细胞替代品为输血服务提供了一个有前途的价值主张，因为它们有望增加血液制品的可用性，消除供体和污染安全风险。在这篇文章中，作者指出，现有的产品存在血管活性等严重缺陷;他们还指出，不基于人类血液的替代品可能会带来更复杂的安全障碍。作者讨论了理想血液替代品的属性以及全氟碳化物的作用机制和现状;他们还回顾了当今开发的所有氧气治疗产品的缺点。
Current demands over the blood supply in developed and developing nations will compound over time. Red cell substitutes shave a promising value proposition for transfusion services, because they hold the promise of increasing the availability of blood products and removing donor and contamination safety risks. In this article, the authors note that existing products suffer from critical shortcomings such as vasoactivity; they also point out that substitutes not based on human blood introduce potentially more complex safety hurdles. The authors discuss the attributes of an ideal blood substitute, and the mechanism and current status of perfluorocarbons; they also review the shortcomings of all oxygen therapeutic products in development today.